We often get questions about where CURE Childhood Cancer has invested its research funding and what that research is teaching us. To help you understand the state of childhood cancer, the status of research projects and what we’re funding, we put together this series of documents. Click on any title to download the PDF.
CURE Investment Fact Sheet
Read about some of our recent research investments at the Aflac Cancer Center, one of the premier pediatric cancer research centers in the United States.
White Paper: Understanding Leukemia – The Most Common Form of Childhood Cancer
Designed to be a primer on leukemia, this white paper provides a starting point to help you understand the progress and challenges in curing this terrible disease.
White Paper: Experimental Immunotherapy-Childhood Neuroblastoma
Researchers from the Children’s Oncology Group (“COG”) have demonstrated that a new experimental immunotherapy treatment resulted in a 20% improvement in cure rates compared to the standard treatment used in the past.
White Paper: Understanding the Scope and Challenges of Childhood Cancer
The basics of childhood cancer – where we’ve come from and the challenges ahead – are discussed in this white paper, with content from CureSearch, the National Cancer Institute and the National Institute of Health.
Research Update: Targeted Therapies – SF1126
This important research is being led by Dr. Donald L. Durden, Scientific Director, Aflac Cancer Center, and his team. Once tested in the laboratory, these drugs can be moved into clinical trials and be made available to all children with cancer. It is however a time-consuming and costly exercise.
White Paper: Targeted Therapy in Pediatric Cancer
By Dr. Donald Durden
Research Summary: Dr. Harry Findley
Understanding how neuroblastoma and pediatric acute lymphoblastic leukemia (ALL) calls become resistant to chemotherapies and find new agents to treat drug-resistance.
Research Summary: Dr. Muxiang Zhou
Learn about molecular mechanisms and signaling pathways that confer tumor promotion and chemotherapy resistance in childhood cancers